Verfügbarkeit: Innovative drug development for headache disorders /

Innovative drug development for headache disorders /:

Migraine treatment improved considerably with the advent of the 'triptans' in the 1990s. While the drugs used previously for headache treatment had efficacy, some compounds had bothersome side effects and their overuse could lead to severe complications. In the early days of the triptans,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Weitere Verfasser:	Olesen, Jes, Ramadan, Nabih
Format:	Elektronisch E-Book
Sprache:	English
Veröffentlicht:	Oxford ; New York : Oxford University Press, 2008.
Schriftenreihe:	Frontiers in headache research ; v. 16.
Schlagworte:	Headache > Chemotherapy. Analgesics. Drug development. Headache Disorders > drug therapy Headache Disorders > prevention & control Analgesics Céphalée > Chimiothérapie. Analgésiques. Médicaments > Développement. HEALTH & FITNESS > Diseases > Nervous System (incl. Brain) MEDICAL > Neurology. Drug development Headache > Chemotherapy Céphalées > traitement médicamenteux. Céphalées > prévention et contrôle. Migraine > Chimiothérapie.
Online-Zugang:	Volltext
Zusammenfassung:	Migraine treatment improved considerably with the advent of the 'triptans' in the 1990s. While the drugs used previously for headache treatment had efficacy, some compounds had bothersome side effects and their overuse could lead to severe complications. In the early days of the triptans, it was widely presumed that migraine was no longer a treatment problem. However, it has gradually been recognized that a significant proportion of patients are not responsive to triptans or do not tolerate them.
Beschreibung:	1 online resource (xii, 227 pages) : illustrations
Bibliographie:	Includes bibliographical references and index.
ISBN:	9780191564628 0191564621

Internformat

MARC


LEADER	00000cam a2200000 a 4500
001	ZDB-4-EBA-ocn801404391
003	OCoLC
005	20241004212047.0
006	m o d
007	cr cnu---unuuu
008	120723s2008 enka ob 001 0 eng d
010			\|z 2008021573
040			\|a N$T \|b eng \|e pn \|c N$T \|d E7B \|d OCLCQ \|d OCLCF \|d NLGGC \|d YDXCP \|d EBLCP \|d IDEBK \|d OCLCQ \|d STBDS \|d TOA \|d AGLDB \|d OCLCO \|d OCLCQ \|d OCLCA \|d STF \|d OCLCO \|d VNS \|d VTS \|d REC \|d OCLCQ \|d OCLCO \|d OCLCQ \|d OCLCA \|d AJS \|d OCLCQ \|d OCLCO \|d INARC \|d OCLCO \|d OCLCQ \|d OCLCO
015			\|a GBA889279 \|2 bnb
016	7		\|a 101474374 \|2 DNLM
016	7		\|a 014669623 \|2 Uk
019			\|a 801363524 \|a 1302077418
020			\|a 9780191564628 \|q (electronic bk.)
020			\|a 0191564621 \|q (electronic bk.)
020			\|z 9780199552764
020			\|z 0199552762
035			\|a (OCoLC)801404391 \|z (OCoLC)801363524 \|z (OCoLC)1302077418
050		4	\|a RC392 \|b .I558 2008eb
060		4	\|a W1 \|b FR945YD v.16 2008
060		4	\|a WL 342 \|b I58 2008
072		7	\|a HEA \|x 039110 \|2 bisacsh
072		7	\|a MED \|x 056000 \|2 bisacsh
082	7		\|a 616.8/491061 \|2 22
049			\|a MAIN
245	0	0	\|a Innovative drug development for headache disorders / \|c edited by Jes Olesen, Nabih Ramadan.
260			\|a Oxford ; \|a New York : \|b Oxford University Press, \|c 2008.
300			\|a 1 online resource (xii, 227 pages) : \|b illustrations
336			\|a text \|b txt \|2 rdacontent
337			\|a computer \|b c \|2 rdamedia
338			\|a online resource \|b cr \|2 rdacarrier
490	1		\|a Frontiers in headache research series ; \|v v. 16
504			\|a Includes bibliographical references and index.
505	0		\|a Effectiveness of different steroid dosage in Tolosa-Hunt syndrome with different phenotypes: some critical points about the new International Headache Society classification / E. Marchioni [and others] -- Discussion summary: trial methodology / Jes Olesen -- Inducible nitric oxide synthase and development of new migraine treatments / Boris A. Chizh -- Mechanisms of cortical spreading depression as targets for migraine therapy / Kevin C. Brennan and Andrew C. Charles -- Tonabersat / Peter R. Blower and Paul C. Sharpe -- Discussion summary: nitric oxide and spreading depression modulators / Nabih Ramadan -- Calcitonin gene-related peptide: relevance for migraine / Jes Olesen and Inger Jansen-Olesen.
505	0		\|a KATP channels and migraine / Inger Jansen-Olesen and Kenneth Beri Ploug -- Antiepileptic drugs and migraine / Michael A. Rogawski -- Discussion summary : ion channel modulators and antiepileptics / Pramod R. Saxena -- Innovative drug development for headache disorders : glutamate / Kirk W. Johnson [and others] -- The modulation of TRPV1 channels by cannabinoid1 receptors / Beatriz Fioravanti and Todd W. Vanderah -- Future targets for headache therapy: prostanoids / Christian Waeber -- Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat / Cristina Tassorelli [and others].
588	0		\|a Print version record.
520			\|a Migraine treatment improved considerably with the advent of the 'triptans' in the 1990s. While the drugs used previously for headache treatment had efficacy, some compounds had bothersome side effects and their overuse could lead to severe complications. In the early days of the triptans, it was widely presumed that migraine was no longer a treatment problem. However, it has gradually been recognized that a significant proportion of patients are not responsive to triptans or do not tolerate them.
650		0	\|a Headache \|x Chemotherapy.
650		0	\|a Analgesics. \|0 http://id.loc.gov/authorities/subjects/sh85004764
650		0	\|a Drug development. \|0 http://id.loc.gov/authorities/subjects/sh97007921
650	1	2	\|a Headache Disorders \|x drug therapy
650	2	2	\|a Headache Disorders \|x prevention & control
650		2	\|a Analgesics \|0 https://id.nlm.nih.gov/mesh/D000700
650		6	\|a Céphalée \|x Chimiothérapie.
650		6	\|a Analgésiques.
650		6	\|a Médicaments \|x Développement.
650		7	\|a HEALTH & FITNESS \|x Diseases \|x Nervous System (incl. Brain) \|2 bisacsh
650		7	\|a MEDICAL \|x Neurology. \|2 bisacsh
650		7	\|a Analgesics \|2 fast
650		7	\|a Drug development \|2 fast
650		7	\|a Headache \|x Chemotherapy \|2 fast
650	1	7	\|a Céphalées \|x traitement médicamenteux. \|2 fmesh
650	2	7	\|a Céphalées \|x prévention et contrôle. \|2 fmesh
650		7	\|a Migraine \|x Chimiothérapie. \|2 ram
650		7	\|a Analgésiques. \|2 ram
700	1		\|a Olesen, Jes.
700	1		\|a Ramadan, Nabih.
776	0	8	\|i Print version: \|t Innovative drug development for headache disorders. \|d Oxford ; New York : Oxford University Press, 2008 \|z 9780199552764 \|w (DLC) 2008021573 \|w (OCoLC)228569514
830		0	\|a Frontiers in headache research ; \|v v. 16. \|0 http://id.loc.gov/authorities/names/n88525294
856	4	0	\|l FWS01 \|p ZDB-4-EBA \|q FWS_PDA_EBA \|u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=467641 \|3 Volltext
938			\|a ProQuest Ebook Central \|b EBLB \|n EBL975568
938			\|a ebrary \|b EBRY \|n ebr10581488
938			\|a EBSCOhost \|b EBSC \|n 467641
938			\|a ProQuest MyiLibrary Digital eBook Collection \|b IDEB \|n 389289
938			\|a Oxford University Press USA \|b OUPR \|n EDZ0000128737
938			\|a YBP Library Services \|b YANK \|n 9316015
938			\|a YBP Library Services \|b YANK \|n 12890334
938			\|a Internet Archive \|b INAR \|n innovativedrugde0000unse
994			\|a 92 \|b GEBAY
912			\|a ZDB-4-EBA
049			\|a DE-863

Datensatz im Suchindex

DE-BY-FWS_katkey	ZDB-4-EBA-ocn801404391
_version_	1816882201079316480
adam_text
any_adam_object
author2	Olesen, Jes Ramadan, Nabih
author2_role
author2_variant	j o jo n r nr
author_facet	Olesen, Jes Ramadan, Nabih
author_sort	Olesen, Jes
building	Verbundindex
bvnumber	localFWS
callnumber-first	R - Medicine
callnumber-label	RC392
callnumber-raw	RC392 .I558 2008eb
callnumber-search	RC392 .I558 2008eb
callnumber-sort	RC 3392 I558 42008EB
callnumber-subject	RC - Internal Medicine
collection	ZDB-4-EBA
contents	Effectiveness of different steroid dosage in Tolosa-Hunt syndrome with different phenotypes: some critical points about the new International Headache Society classification / E. Marchioni [and others] -- Discussion summary: trial methodology / Jes Olesen -- Inducible nitric oxide synthase and development of new migraine treatments / Boris A. Chizh -- Mechanisms of cortical spreading depression as targets for migraine therapy / Kevin C. Brennan and Andrew C. Charles -- Tonabersat / Peter R. Blower and Paul C. Sharpe -- Discussion summary: nitric oxide and spreading depression modulators / Nabih Ramadan -- Calcitonin gene-related peptide: relevance for migraine / Jes Olesen and Inger Jansen-Olesen. KATP channels and migraine / Inger Jansen-Olesen and Kenneth Beri Ploug -- Antiepileptic drugs and migraine / Michael A. Rogawski -- Discussion summary : ion channel modulators and antiepileptics / Pramod R. Saxena -- Innovative drug development for headache disorders : glutamate / Kirk W. Johnson [and others] -- The modulation of TRPV1 channels by cannabinoid1 receptors / Beatriz Fioravanti and Todd W. Vanderah -- Future targets for headache therapy: prostanoids / Christian Waeber -- Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat / Cristina Tassorelli [and others].
ctrlnum	(OCoLC)801404391
dewey-full	616.8/491061
dewey-hundreds	600 - Technology (Applied sciences)
dewey-ones	616 - Diseases
dewey-raw	616.8/491061
dewey-search	616.8/491061
dewey-sort	3616.8 6491061
dewey-tens	610 - Medicine and health
discipline	Medizin
format	Electronic eBook
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05353cam a2200841 a 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn801404391</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">120723s2008 enka ob 001 0 eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="z"> 2008021573</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">E7B</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCF</subfield><subfield code="d">NLGGC</subfield><subfield code="d">YDXCP</subfield><subfield code="d">EBLCP</subfield><subfield code="d">IDEBK</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">STBDS</subfield><subfield code="d">TOA</subfield><subfield code="d">AGLDB</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">STF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">VNS</subfield><subfield code="d">VTS</subfield><subfield code="d">REC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">AJS</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">INARC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">GBA889279</subfield><subfield code="2">bnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">101474374</subfield><subfield code="2">DNLM</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">014669623</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">801363524</subfield><subfield code="a">1302077418</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780191564628</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0191564621</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780199552764</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0199552762</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)801404391</subfield><subfield code="z">(OCoLC)801363524</subfield><subfield code="z">(OCoLC)1302077418</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC392</subfield><subfield code="b">.I558 2008eb</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">W1</subfield><subfield code="b">FR945YD v.16 2008</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">WL 342</subfield><subfield code="b">I58 2008</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039110</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">056000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.8/491061</subfield><subfield code="2">22</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Innovative drug development for headache disorders /</subfield><subfield code="c">edited by Jes Olesen, Nabih Ramadan.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Oxford ;</subfield><subfield code="a">New York :</subfield><subfield code="b">Oxford University Press,</subfield><subfield code="c">2008.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xii, 227 pages) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers in headache research series ;</subfield><subfield code="v">v. 16</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Effectiveness of different steroid dosage in Tolosa-Hunt syndrome with different phenotypes: some critical points about the new International Headache Society classification / E. Marchioni [and others] -- Discussion summary: trial methodology / Jes Olesen -- Inducible nitric oxide synthase and development of new migraine treatments / Boris A. Chizh -- Mechanisms of cortical spreading depression as targets for migraine therapy / Kevin C. Brennan and Andrew C. Charles -- Tonabersat / Peter R. Blower and Paul C. Sharpe -- Discussion summary: nitric oxide and spreading depression modulators / Nabih Ramadan -- Calcitonin gene-related peptide: relevance for migraine / Jes Olesen and Inger Jansen-Olesen.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">KATP channels and migraine / Inger Jansen-Olesen and Kenneth Beri Ploug -- Antiepileptic drugs and migraine / Michael A. Rogawski -- Discussion summary : ion channel modulators and antiepileptics / Pramod R. Saxena -- Innovative drug development for headache disorders : glutamate / Kirk W. Johnson [and others] -- The modulation of TRPV1 channels by cannabinoid1 receptors / Beatriz Fioravanti and Todd W. Vanderah -- Future targets for headache therapy: prostanoids / Christian Waeber -- Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat / Cristina Tassorelli [and others].</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Migraine treatment improved considerably with the advent of the 'triptans' in the 1990s. While the drugs used previously for headache treatment had efficacy, some compounds had bothersome side effects and their overuse could lead to severe complications. In the early days of the triptans, it was widely presumed that migraine was no longer a treatment problem. However, it has gradually been recognized that a significant proportion of patients are not responsive to triptans or do not tolerate them.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Headache</subfield><subfield code="x">Chemotherapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Analgesics.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85004764</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug development.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh97007921</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Headache Disorders</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Headache Disorders</subfield><subfield code="x">prevention & control</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Analgesics</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D000700</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Céphalée</subfield><subfield code="x">Chimiothérapie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Analgésiques.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Développement.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS</subfield><subfield code="x">Diseases</subfield><subfield code="x">Nervous System (incl. Brain)</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Neurology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Analgesics</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug development</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Headache</subfield><subfield code="x">Chemotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1="1" ind2="7"><subfield code="a">Céphalées</subfield><subfield code="x">traitement médicamenteux.</subfield><subfield code="2">fmesh</subfield></datafield><datafield tag="650" ind1="2" ind2="7"><subfield code="a">Céphalées</subfield><subfield code="x">prévention et contrôle.</subfield><subfield code="2">fmesh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Migraine</subfield><subfield code="x">Chimiothérapie.</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Analgésiques.</subfield><subfield code="2">ram</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olesen, Jes.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramadan, Nabih.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Innovative drug development for headache disorders.</subfield><subfield code="d">Oxford ; New York : Oxford University Press, 2008</subfield><subfield code="z">9780199552764</subfield><subfield code="w">(DLC) 2008021573</subfield><subfield code="w">(OCoLC)228569514</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Frontiers in headache research ;</subfield><subfield code="v">v. 16.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n88525294</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=467641</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL975568</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10581488</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">467641</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest MyiLibrary Digital eBook Collection</subfield><subfield code="b">IDEB</subfield><subfield code="n">389289</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Oxford University Press USA</subfield><subfield code="b">OUPR</subfield><subfield code="n">EDZ0000128737</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">9316015</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">12890334</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Internet Archive</subfield><subfield code="b">INAR</subfield><subfield code="n">innovativedrugde0000unse</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection>
id	ZDB-4-EBA-ocn801404391
illustrated	Illustrated
indexdate	2024-11-27T13:24:50Z
institution	BVB
isbn	9780191564628 0191564621
language	English
oclc_num	801404391
open_access_boolean
owner	MAIN DE-863 DE-BY-FWS
owner_facet	MAIN DE-863 DE-BY-FWS
physical	1 online resource (xii, 227 pages) : illustrations
psigel	ZDB-4-EBA
publishDate	2008
publishDateSearch	2008
publishDateSort	2008
publisher	Oxford University Press,
record_format	marc
series	Frontiers in headache research ;
series2	Frontiers in headache research series ;
spelling	Innovative drug development for headache disorders / edited by Jes Olesen, Nabih Ramadan. Oxford ; New York : Oxford University Press, 2008. 1 online resource (xii, 227 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers in headache research series ; v. 16 Includes bibliographical references and index. Effectiveness of different steroid dosage in Tolosa-Hunt syndrome with different phenotypes: some critical points about the new International Headache Society classification / E. Marchioni [and others] -- Discussion summary: trial methodology / Jes Olesen -- Inducible nitric oxide synthase and development of new migraine treatments / Boris A. Chizh -- Mechanisms of cortical spreading depression as targets for migraine therapy / Kevin C. Brennan and Andrew C. Charles -- Tonabersat / Peter R. Blower and Paul C. Sharpe -- Discussion summary: nitric oxide and spreading depression modulators / Nabih Ramadan -- Calcitonin gene-related peptide: relevance for migraine / Jes Olesen and Inger Jansen-Olesen. KATP channels and migraine / Inger Jansen-Olesen and Kenneth Beri Ploug -- Antiepileptic drugs and migraine / Michael A. Rogawski -- Discussion summary : ion channel modulators and antiepileptics / Pramod R. Saxena -- Innovative drug development for headache disorders : glutamate / Kirk W. Johnson [and others] -- The modulation of TRPV1 channels by cannabinoid1 receptors / Beatriz Fioravanti and Todd W. Vanderah -- Future targets for headache therapy: prostanoids / Christian Waeber -- Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat / Cristina Tassorelli [and others]. Print version record. Migraine treatment improved considerably with the advent of the 'triptans' in the 1990s. While the drugs used previously for headache treatment had efficacy, some compounds had bothersome side effects and their overuse could lead to severe complications. In the early days of the triptans, it was widely presumed that migraine was no longer a treatment problem. However, it has gradually been recognized that a significant proportion of patients are not responsive to triptans or do not tolerate them. Headache Chemotherapy. Analgesics. http://id.loc.gov/authorities/subjects/sh85004764 Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Headache Disorders drug therapy Headache Disorders prevention & control Analgesics https://id.nlm.nih.gov/mesh/D000700 Céphalée Chimiothérapie. Analgésiques. Médicaments Développement. HEALTH & FITNESS Diseases Nervous System (incl. Brain) bisacsh MEDICAL Neurology. bisacsh Analgesics fast Drug development fast Headache Chemotherapy fast Céphalées traitement médicamenteux. fmesh Céphalées prévention et contrôle. fmesh Migraine Chimiothérapie. ram Analgésiques. ram Olesen, Jes. Ramadan, Nabih. Print version: Innovative drug development for headache disorders. Oxford ; New York : Oxford University Press, 2008 9780199552764 (DLC) 2008021573 (OCoLC)228569514 Frontiers in headache research ; v. 16. http://id.loc.gov/authorities/names/n88525294 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=467641 Volltext
spellingShingle	Innovative drug development for headache disorders / Frontiers in headache research ; Effectiveness of different steroid dosage in Tolosa-Hunt syndrome with different phenotypes: some critical points about the new International Headache Society classification / E. Marchioni [and others] -- Discussion summary: trial methodology / Jes Olesen -- Inducible nitric oxide synthase and development of new migraine treatments / Boris A. Chizh -- Mechanisms of cortical spreading depression as targets for migraine therapy / Kevin C. Brennan and Andrew C. Charles -- Tonabersat / Peter R. Blower and Paul C. Sharpe -- Discussion summary: nitric oxide and spreading depression modulators / Nabih Ramadan -- Calcitonin gene-related peptide: relevance for migraine / Jes Olesen and Inger Jansen-Olesen. KATP channels and migraine / Inger Jansen-Olesen and Kenneth Beri Ploug -- Antiepileptic drugs and migraine / Michael A. Rogawski -- Discussion summary : ion channel modulators and antiepileptics / Pramod R. Saxena -- Innovative drug development for headache disorders : glutamate / Kirk W. Johnson [and others] -- The modulation of TRPV1 channels by cannabinoid1 receptors / Beatriz Fioravanti and Todd W. Vanderah -- Future targets for headache therapy: prostanoids / Christian Waeber -- Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat / Cristina Tassorelli [and others]. Headache Chemotherapy. Analgesics. http://id.loc.gov/authorities/subjects/sh85004764 Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Headache Disorders drug therapy Headache Disorders prevention & control Analgesics https://id.nlm.nih.gov/mesh/D000700 Céphalée Chimiothérapie. Analgésiques. Médicaments Développement. HEALTH & FITNESS Diseases Nervous System (incl. Brain) bisacsh MEDICAL Neurology. bisacsh Analgesics fast Drug development fast Headache Chemotherapy fast Céphalées traitement médicamenteux. fmesh Céphalées prévention et contrôle. fmesh Migraine Chimiothérapie. ram Analgésiques. ram
subject_GND	http://id.loc.gov/authorities/subjects/sh85004764 http://id.loc.gov/authorities/subjects/sh97007921 https://id.nlm.nih.gov/mesh/D000700
title	Innovative drug development for headache disorders /
title_auth	Innovative drug development for headache disorders /
title_exact_search	Innovative drug development for headache disorders /
title_full	Innovative drug development for headache disorders / edited by Jes Olesen, Nabih Ramadan.
title_fullStr	Innovative drug development for headache disorders / edited by Jes Olesen, Nabih Ramadan.
title_full_unstemmed	Innovative drug development for headache disorders / edited by Jes Olesen, Nabih Ramadan.
title_short	Innovative drug development for headache disorders /
title_sort	innovative drug development for headache disorders
topic	Headache Chemotherapy. Analgesics. http://id.loc.gov/authorities/subjects/sh85004764 Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Headache Disorders drug therapy Headache Disorders prevention & control Analgesics https://id.nlm.nih.gov/mesh/D000700 Céphalée Chimiothérapie. Analgésiques. Médicaments Développement. HEALTH & FITNESS Diseases Nervous System (incl. Brain) bisacsh MEDICAL Neurology. bisacsh Analgesics fast Drug development fast Headache Chemotherapy fast Céphalées traitement médicamenteux. fmesh Céphalées prévention et contrôle. fmesh Migraine Chimiothérapie. ram Analgésiques. ram
topic_facet	Headache Chemotherapy. Analgesics. Drug development. Headache Disorders drug therapy Headache Disorders prevention & control Analgesics Céphalée Chimiothérapie. Analgésiques. Médicaments Développement. HEALTH & FITNESS Diseases Nervous System (incl. Brain) MEDICAL Neurology. Drug development Headache Chemotherapy Céphalées traitement médicamenteux. Céphalées prévention et contrôle. Migraine Chimiothérapie.
url	https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=467641
work_keys_str_mv	AT olesenjes innovativedrugdevelopmentforheadachedisorders AT ramadannabih innovativedrugdevelopmentforheadachedisorders

Verfügbarkeit

Es ist kein Print-Exemplar vorhanden.

Volltext öffnen

MARC

Datensatz im Suchindex

Es ist kein Print-Exemplar vorhanden.

Ähnliche Einträge